Ways and Means Advances Bipartisan Prescription Drug Pricing LegislationNeal, Brady laud bill that will increase transparency in drug pricing for consumers
Washington, DC,
April 9, 2019
Today, the House Committee on Ways & Means unanimously passed the bipartisan Prescription Drug STAR Act. H.R. 2113 addresses key issues related to transparency and public reporting of information in order to improve accountability and ensure consumers, purchasers, payers, and taxpayers have a better understanding of this opaque market. “Today, our committee put aside our ideological differences and passed the bipartisan Prescription Drug STAR Act, a first step in addressing the high cost of prescription drugs affecting consumers in Massachusetts, Texas, and across the country by improving transparency for patients,” said Chairman Neal and Ranking Member Brady. “This bipartisan effort brings sunlight across the health care supply chain, from pharmaceutical manufacturers to pharmacy benefit managers, to help reduce costs for families. There is more work to be done on this bill and on this issue and we look forward to continuing our bipartisan work to address other drug pricing and pressing health care issues the American people face.” The STAR Act would:
The STAR Act is supported by numerous national organizations including AARP, American Hospital Association, ERISA Industry Committee, National Community Pharmacists Association, and Federation of American Hospitals, among others. Full text of the Prescription Drug STAR Act can be found HERE. Section-by-Section can be found HERE. ### |